Diakonos Oncology Secures $20M to Accelerate Revolutionary DOC1021 Therapy for Glioblastoma and Pancreatic Cancer

Diakonos Oncology is thrilled to announce a significant milestone in its journey toward revolutionizing cancer care by raising $20,000,000 in its latest funding round. This substantial investment underscores the confidence that investors have in Diakonos Oncology’s groundbreaking approach to treating some of the most aggressive cancers. At the heart of this innovation is DOC1021, an FDA Fast Track-designated “double-loaded” dendritic cell therapy designed for glioblastoma (GBM) and pancreatic cancer (PDAC). This personalized, autologous treatment has already demonstrated exceptional promise in early trials, achieving an impressive 88% 12-month survival rate in patients with unmethylated GBM, with 38% of these patients still alive after 18–29 months, even in the face of one of the most challenging cancer diagnoses. The funds raised will be strategically allocated to accelerate the initiation and expansion of Phase II clinical trials, set to commence in Q1 2025 at leading GBM centers across the nation. This critical stage in the clinical development of DOC1021 is poised to further refine dosing strategies, optimize patient selection criteria, and potentially broaden the therapy’s application in treating aggressive cancers. Moreover, the investment will support enhanced manufacturing capabilities and bolster regulatory efforts to ensure a swift and efficient path toward broader market availability. With this new capital infusion, Diakonos Oncology is well-positioned to not only advance its promising therapy but also set a new benchmark in personalized cancer treatment, continuing its mission to offer hope and improved outcomes for patients battling some of the most deadly forms of cancer.